Vividion Therapeutics, Inc. announced that it will issue 47,959,011 series D preferred shares at issue price of $1.62342 per share for the gross proceeds $77,857,617.63762 in funding on December 12, 2019. The shares are convertible, participating, redeemable and non-cumulative. The shares carry non-cumulative dividend value of $0.1287 per annum per share.

The shares will be convertible in common shares at a price of $1.62342 per share. The company will receive $47,857,619 pursuant to exemption provided under Regulation D.